v3.25.4
Summary of Significant Accounting Policies - Additional Information (Details)
12 Months Ended
Dec. 31, 2025
USD ($)
item
shares
Dec. 31, 2024
USD ($)
shares
Summary of Significant Accounting Policies    
Accumulated deficit $ (435,980,000) $ (380,136,000)
Cash, cash equivalents and marketable securities $ 41,800,000  
Number of accredited financial institutions that are federally insured | item 2  
Property and Equipment, Net    
Impairment loss recognized $ 0 $ 1,200,000
Preferred Stock    
Preferred stock, shares outstanding | shares 0 0
Research and Development Costs, Including Clinical Trial Accruals and Acquired in Process Research and Development    
Accrued clinical trial costs $ 900,000  
Income Taxes    
Uncertain income tax benefits, interest or penalties $ 0